Literature DB >> 28368381

Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT.

J El-Cheikh1, R Massoud1, E Fares1, N Kreidieh2, R Mahfouz2, M Charafeddine1, M A Kharfan-Dabaja3, A Bazarbachi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28368381     DOI： 10.1038/bmt.2017.31

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT.

Authors:  B Tessoulin; J Delaunay; P Chevallier; M Loirat; S Ayari; P Peterlin; S Le Gouill; T Gastinne; P Moreau; M Mohty; T Guillaume
Journal:  Bone Marrow Transplant       Date:  2014-02-03       Impact factor: 5.483

2.  Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).

Authors:  Oliver C Goodyear; Mike Dennis; Nadira Y Jilani; Justin Loke; Shamyla Siddique; Gordon Ryan; Jane Nunnick; Rahela Khanum; Manoj Raghavan; Mark Cook; John A Snowden; Mike Griffiths; Nigel Russell; John Yin; Charles Crawley; Gordon Cook; Paresh Vyas; Paul Moss; Ram Malladi; Charles F Craddock
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

3.  Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.

Authors:  Thomas Schroeder; Elena Rachlis; Gesine Bug; Matthias Stelljes; Stefan Klein; Nina Kristin Steckel; Dominik Wolf; Mark Ringhoffer; Akos Czibere; Kathrin Nachtkamp; Ariane Dienst; Mustafa Kondakci; Michael Stadler; Uwe Platzbecker; Lutz Uharek; Thomas Luft; Roland Fenk; Ulrich Germing; Martin Bornhäuser; Nicolaus Kröger; Dietrich W Beelen; Rainer Haas; Guido Kobbe
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-23       Impact factor: 5.742

4.  Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.

Authors:  Nelli Bejanyan; Daniel J Weisdorf; Brent R Logan; Hai-Lin Wang; Steven M Devine; Marcos de Lima; Donald W Bunjes; Mei-Jie Zhang
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-15       Impact factor: 5.742

5.  5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.

Authors:  Javier Bolaños-Meade; B Douglas Smith; Steven D Gore; Michael A McDevitt; Leo Luznik; Ephraim J Fuchs; Richard J Jones
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-15       Impact factor: 5.742

6.  Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.

Authors:  Elias Jabbour; Sergio Giralt; Hagop Kantarjian; Guillermo Garcia-Manero; Madan Jagasia; Partow Kebriaei; Leandro de Padua; Elizabeth J Shpall; Richard Champlin; Marcos de Lima
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

7.  Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.

Authors:  M Lübbert; H Bertz; R Wäsch; R Marks; B Rüter; R Claus; J Finke
Journal:  Bone Marrow Transplant       Date:  2009-08-31       Impact factor: 5.483

8.  Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Brent R Logan; Zhiwei Wang; Edwin P Alyea; Matt E Kalaycio; Richard T Maziarz; Joseph H Antin; Robert J Soiffer; Daniel J Weisdorf; J Douglas Rizzo; Mary M Horowitz; Wael Saber
Journal:  Blood       Date:  2014-04-17       Impact factor: 22.113

9.  Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.

Authors:  T Ruutu; L C de Wreede; A van Biezen; R Brand; M Mohty; P Dreger; R Duarte; C Peters; L Garderet; S Schönland; A Gratwohl; D Niederwieser; T de Witte; N Kröger
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

10.  Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Authors:  Charles Craddock; Nadira Jilani; Shamyla Siddique; Christina Yap; Josephine Khan; Sandeep Nagra; Janice Ward; Paul Ferguson; Peter Hazlewood; Richard Buka; Paresh Vyas; Oliver Goodyear; Eleni Tholouli; Charles Crawley; Nigel Russell; Jenny Byrne; Ram Malladi; John Snowden; Mike Dennis
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-09       Impact factor: 5.742
View more
  11 in total

Review 1.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

2.  Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.

Authors:  Kevin-James Wattebled; Elodie Drumez; Valérie Coiteux; Léonardo Magro; Micha Srour; Paul Chauvet; Bruno Quesnel; Alain Duhamel; Ibrahim Yakoub-Agha; David Beauvais
Journal:  Ann Hematol       Date:  2022-03-29       Impact factor: 3.673

Review 3.  Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

Authors:  Joseph C Rimando; Matthew J Christopher; Michael P Rettig; John F DiPersio
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

Review 4.  Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.

Authors:  Ying-Jun Chang; Xiang-Yu Zhao; Xiao-Jun Huang
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

Review 5.  BMT for Myelodysplastic Syndrome: When and Where and How.

Authors:  Akriti G Jain; Hany Elmariah
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

6.  Low-Dose 5-Aza and DZnep Alleviate Acute Graft-Versus-Host Disease With Less Side Effects Through Altering T-Cell Differentiation.

Authors:  Qing Ya Wang; Hui Hui Liu; Yu Jun Dong; Ze Yin Liang; Yue Yin; Wei Liu; Qing Yun Wang; Qian Wang; Yu Hua Sun; Wei Lin Xu; Na Han; Yuan Li; Han Yun Ren
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

Review 7.  Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation.

Authors:  Øystein Bruserud; Galina Tsykunova; Maria Hernandez-Valladares; Hakon Reikvam; Tor Henrik Anderson Tvedt
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-02

Review 8.  Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Wei Shi; Weiwei Jin; Linghui Xia; Yu Hu
Journal:  Acta Pharm Sin B       Date:  2020-06-30       Impact factor: 11.413

9.  Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease.

Authors:  Qing Ya Wang; Yuan Li; Ze Yin Liang; Yue Yin; Wei Liu; Qian Wang; Yu Jun Dong; Yu Hua Sun; Wei Lin Xu; Han Yun Ren
Journal:  Cancer Manag Res       Date:  2019-12-04       Impact factor: 3.989

Review 10.  Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!

Authors:  Iman Abou Dalle; Jean El Cheikh; Ali Bazarbachi
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.